APRE (Aprea Therapeutics) Stock Based Compensation: $0.46 Mil (TTM As of Mar. 2026)


APRE Aprea Therapeutics Inc APRE
26 GF Score
Price $0.74
! 1 Warning Sign
View Full Analysis

What is Aprea Therapeutics Stock Based Compensation?

Aprea Therapeutics APRE +2.77% 26 Stock Based Compensation is $0.46 Mil as of Mar. 2026. GuruFocus rates APRE with a GF Score™ of 26/100. The stock has 1 warning sign investors should review.

Aprea Therapeutics's Stock Based Compensation for the three months ended in Mar. 2026 was $0.10 Mil. Its Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 was $0.46 Mil.

Aprea Therapeutics Stock Based Compensation Related Terms

Aprea Therapeutics Stock Based Compensation Historical Data

* Premium members only.

The historical data trend for Aprea Therapeutics's Stock Based Compensation can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Aprea Therapeutics Stock Based Compensation Chart

Aprea Therapeutics Annual Data
Trend Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
Stock Based Compensation
Get a 7-Day Free Trial Premium Member Only 7.81 16.98 0.44 0.49 0.48

Aprea Therapeutics Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
Stock Based Compensation Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.12 0.14 0.11 0.11 0.10
APRE
26GF Score
Aprea Therapeutics Inc APRE
Stock Based Compensation is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Aprea Therapeutics Stock Based Compensation Calculation

Stock Based Compensation is a way corporations use stock options to reward employees. It provides executives and employees the opportunity to share in the growth of the company and, if structured properly, can align their interests with the interests of the company's shareholders and investors, without burning the company's cash on hand.

Stock Based Compensation for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was $0.46 Mil.

What does a Stock Based Compensation of $0.46 Mil mean?
Aprea Therapeutics (APRE) has a Stock Based Compensation of $0.46 Mil as of Mar. 2026. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Aprea Therapeutics and its competitors.
Is Aprea Therapeutics' Stock Based Compensation too high?
Aprea Therapeutics' current Stock Based Compensation is $0.46 Mil. Overall, Aprea Therapeutics has a GF Score™ of 26/100, reflecting its overall financial health beyond just this single metric.
How does Aprea Therapeutics' Stock Based Compensation compare to JSPR and CVKD?
Aprea Therapeutics' Stock Based Compensation of $0.46 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Stock Based Compensation for a Biotechnology company?
A good Stock Based Compensation depends on the Biotechnology industry context. However, Stock Based Compensation should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Stock Based Compensation mean?
A high Stock Based Compensation can signal that a stock is expensive relative to its fundamentals. Stock based compensation is the amount of company stock issued as employee benefits. View historical data for Aprea Therapeutics and its competitors. Aprea Therapeutics's current Stock Based Compensation is $0.46 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Aprea Therapeutics stock overvalued right now?
Aprea Therapeutics (APRE) has a current Stock Based Compensation of $0.46 Mil. The current Stock Based Compensation is $0.46 Mil. Aprea Therapeutics' overall GF Score™ is 26/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Stock Based Compensation calculated?
Stock Based Compensation is calculated from a company's financial statements. For Aprea Therapeutics (APRE), the current Stock Based Compensation is $0.46 Mil as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Aprea Therapeutics Business Description

Address 3805 Old Easton Road, Doylestown, PA, USA, 18902
Aprea Therapeutics Inc is a clinical-stage precision medicine oncology company focused on the discovery and development of targeted therapies for patients with biomarker-defined cancers. It develops small molecule inhibitors designed to exploit genetic mutations in cancer to widen the therapeutic window and is intended to make treatments more effective at destroying cancer cells while sparing healthy tissue. The company's pipeline of clinical and preclinical programs includes APR-1051, a WEE1 inhibitor; ATRN-119 (Mosipasertib), an oral small molecule inhibitor of ataxia telangiectasia and Rad3-related, or ATR; and an early-stage program, APR-1602. These candidates are being developed for broad applications in cancer treatment.
26GF Score

Get the complete analysis for APRE

Stock Based Compensation is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$0.74
Price